ArticleScience immunology2023
Clonally expanded CD38
Open access · goldAbstract read
In one paragraph
Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 60 citations in OpenAlex.
- Balancing immunosuppression and cancer survival in the treatment of immune checkpoint inhibitor-associated inflammatory arthritis.EULAR rheumatology open · 2026Review
- Immune Hallmarks of Recurrent Immune Checkpoint Inhibitor-Mediated Inflammatory Arthritis.Cancer immunology research · 2026Article
- Delayed and multisystem immune-related adverse events in MSI-high colon cancer treated with nivolumab plus ipilimumab.Clinical journal of gastroenterology · 2026Article
- Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Review
- Optimizing management of immune checkpoint inhibitor-induced inflammatory arthritis: A case series and literature review.Experimental and therapeutic medicine · 2026Article
- IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis.The Journal of clinical investigation · 2026Article
- IL-6 in Checkpoint Myocarditis: A Promising Biomarker and Therapeutic Target.JACC. CardioOncology · 2026Article
- Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study.Journal for immunotherapy of cancer · 2026Observational
- Checkpoint blockade-related CNS adverse events are characterized by neurotoxic T helper cells with sustained neuroantigen reactivity.Cell reports. Medicine · 2026Article
- Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies.Science advances · 2026Article
- Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.Nature medicine · 2026Article
- Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries.Journal for immunotherapy of cancer · 2026Article
- Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma.JCI insight · 2026Article
- Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.Communications medicine · 2025Article
- Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases.Nature reviews. Rheumatology · 2025Review
- Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma.bioRxiv : the preprint server for biology · 2025Article
- Neuromuscular complications associated with cancer immunotherapy.Journal of the National Cancer Center · 2025Review
- Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies.medRxiv : the preprint server for health sciences · 2025Article
- Article
- Type I interferon drives T cell cytotoxicity by upregulation of interferon regulatory factor 7 in autoimmune kidney diseases in mice.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 3 countries.
Runci WangDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9536-2845
Anvita SingarajuHSS Research Institute, Hospital for Special Surgery, New York, NY 10021, USA.ORCID 0000-0002-3109-6354
Kathryne E MarksDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-1524-7159
Lorien ShakibHSS Research Institute, Hospital for Special Surgery, New York, NY 10021, USA.ORCID 0000-0003-2502-2049
Garrett DunlapDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-2627-0506
Ifeoluwakiisi AdejoorinDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-8967-5896
Stinne R GreisenDepartment of Biomedicine, Aarhus University / Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-2922-3307
Lin ChenDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5072-4152
Aidan K TirpackMedical School at Campbell University School of Osteopathic Medicine, Lillington, NC 27546, USA.ORCID 0000-0001-9444-3555
Carlos AudeDivision of Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-1253-1998
Miriam R FeinHSS Research Institute, Hospital for Special Surgery, New York, NY 10021, USA.ORCID 0000-0003-3403-8798
Derrick J ToddDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-2290-2235
Lindsey MacFarlaneDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-8398-3804
Susan M GoodmanDivision of Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-1197-7864
Edward F DiCarloDivision of Pathology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY 10021, USA.
Elena M MassarottiDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0009-0002-6106-5396
Jeffrey A SparksDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5556-4618
A Helena JonssonDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9558-2474
Michael B BrennerDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-6202-8445
Michael A PostowMelanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-3367-7961
Karmela K ChanDivision of Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-8619-8588
Anne R BassDivision of Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-3225-8351
Laura T DonlinHSS Research Institute, Hospital for Special Surgery, New York, NY 10021, USA.ORCID 0000-0002-1428-090X
Deepak A RaoDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9672-7746
Brigham and Women's Hospital · USHospital for Special Surgery · USAarhus University Hospital · DKCampbell University · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MVERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8MJoint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4MRheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7MImmunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9MMacrophages in human autoimmune tissue pathologyR01AI148435 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI Laura T. Donlin · 2020 to 2026
$2.8MNewly Identified T Peripheral Helper (Tph) Cells in Rheumatoid ArthritisR01AR073290 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BRENNER, MICHAEL B. · 2018 to 2022
$2.6MMolecular control of CD4 T cell ability to help B cellsK08AR072791 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI RAO, DEEPAK ANGARA · 2018 to 2022
$764kNCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI148435NIAMS NIH HHS K08 AR072791NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR073290NIAMS NIH HHS R01 AR077607NIAMS NIH HHS R01 AR080659
Abstract
Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti-PD-1 antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms mediating such iatrogenic autoimmunity and their overlap with spontaneous autoimmune diseases remain unclear. Here, we compared T cells from the joints of 20 patients with an inflammatory arthritis induced by ICI therapy (ICI-arthritis) with two archetypal autoimmune arthritides, rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Single-cell transcriptomic and antigen receptor repertoire analyses highlighted clonal expansion of an activated effector CD8 T cell population in the joints and blood of patients with ICI-arthritis. These cells were identified as CD38
Indexed as
Arthritis, PsoriaticArthritis, RheumatoidCD8-Positive T-LymphocytesHumansSynovial FluidT-Lymphocytes, Cytotoxic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.